30 results on '"Linda Sande"'
Search Results
2. The SENTINEL study of differentiated service delivery models for HIV treatment in Malawi, South Africa, and Zambia: research protocol for a prospective cohort study
- Author
-
Sophie Pascoe, Amy Huber, Idah Mokhele, Nkgomeleng Lekodeba, Vinolia Ntjikelane, Linda Sande, Timothy Tchereni, Prudence Haimbe, AMBIT SENTINEL study team, and Sydney Rosen
- Subjects
HIV ,Differentiated service delivery ,Malawi ,South Africa ,Zambia ,Antiretroviral therapy ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Many countries in sub-Saharan Africa are rapidly scaling up “differentiated service delivery” (DSD) models for HIV treatment to improve the quality of care, increase access, reduce costs, and support the continued expansion and sustainability of antiretroviral therapy (ART) programs. Although there is some published evidence about the health outcomes of patients in DSD models, little is known about their impacts on healthcare providers’ job satisfaction, patients’ quality of life, costs to providers or patients, or how DSD models affect resource allocation at the facility level. Methods SENTINEL is a multi-year observational study that will collect detailed data about DSD models for ART delivery and related services from 12 healthcare facilities in Malawi, 24 in South Africa, and 12 in Zambia. The first round of SENTINEL included a patient survey, provider survey, provider time-and-motion observations, and facility resource use inventory. A survey of clients testing for HIV and a supplement to the facility resource use component to describe service delivery integration will be added for the second round. The patient survey will ask up to 10 patients enrolled in each DSD model at each study site about their experiences in HIV care and in DSD models, costs incurred seeking treatment, and preferences for HIV service delivery. The provider survey will ask up to 10 providers per site about the impact of DSD models on their positions and clinics. The time-and-motion component will directly observe the time use of a sample of providers implementing DSD models. Finally, the resource utilization component will collect facility-level data about DSD model availability and enrollment and the human and other resources needed to implement them. SENTINEL is planned to include four or more approximately annual rounds of data collection between 2021 and 2026. Discussion As national DSD programs for HIV treatment mature, it is important to understand how individual healthcare facilities are interpreting and implementing national guidelines and how healthcare workers and clients are adapting to new models of service delivery. SENTINEL will help policy makers and program managers understand the benefits and costs of differentiated service delivery and improve resource allocation going forward.
- Published
- 2023
- Full Text
- View/download PDF
3. Patterns of engagement in care during clients' first 12 months after HIV treatment initiation in South Africa: A retrospective cohort analysis using routinely collected data.
- Author
-
Mhairi Maskew, Mariet Benade, Amy Huber, Sophie Pascoe, Linda Sande, Lufuno Malala, Musa Manganye, and Sydney Rosen
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Retention on antiretroviral therapy (ART) during the early treatment period is one of the most serious challenges facing HIV programs, but the timing and patterns of early disengagement from care remain poorly understood. We describe patterns of engagement in HIV care during the first year after treatment initiation. We analysed retrospective datasets of routinely collected electronic medical register (EMR) data for ≥18-year-old clients who initiated ART at public sector clinics in South Africa after 01/01/2018 and had ≥14 months of potential follow-up. Using scheduled visit dates, we characterized engagement in care as continuous (no treatment interruption), cyclical (at least one visit >28 days late with a return visit observed) or disengaged (visit not attended and no evidence of return). We report 6- and 12-month patterns of retention in care and viral suppression. Among 35,830 participants (65% female, median age 33), in months 0-6, 59% were continuously in care, 14% had engaged cyclically, 11% had transferred to another facility, 1% had died, and 16% had disengaged from care at the initiating facility. Among disengagers in the first 6 months, 58% did not return after their initiation visit. By 12 months after initiation, the overall proportion disengaged was 23%, 45% were classified as continuously engaged in months 7-12, and only 38% of the cohort had maintained continuous engagement at both the 6- and 12-month endpoints. Participants who were cyclically engaged in months 0-6 were nearly twice as likely to disengage in months 7-12 as were continuous engagers in months 0-6 (relative risk 1.76, 95% CI:1.61-1.91) and were more likely to have an unsuppressed viral load by 12 months on ART (RR = 1.28; 95% CI1.13-1.44). The needs of continuous and cyclical engagers and those disengaging at different timepoints may vary and require different interventions or models of care.
- Published
- 2024
- Full Text
- View/download PDF
4. Preferences for services in a patient’s first six months on antiretroviral therapy for HIV in South Africa and Zambia (PREFER): research protocol for a prospective observational cohort study [version 2; peer review: 2 approved]
- Author
-
Vinolia Ntjikelane, Mhairi Maskew, Prudence Haimbe, Nancy Scott, Allison Juntunen, Pamfred Hasweeka, Linda Sande, Hilda Shakewelele, Priscilla Lumano-Mulenga, Sydney Rosen, Mariet Benade, and Mpande Mukumbwa-Mwenechanya
- Subjects
HIV ,South Africa ,Zambia ,antiretroviral therapy ,retention ,models of care ,eng ,Medicine - Abstract
Background For patients on HIV treatment in sub-Saharan Africa, the highest risk for loss from care remains the first six months after antiretroviral (ART) initiation, when patients are not yet eligible for differentiated service delivery (DSD) models that offer lower-burden, patient-centred care and thus improve treatment outcomes. To reduce early disengagement from care, the PREFER study will use a sequential mixed-methods approach to describe the characteristics, needs, concerns, and preferences of patients in South Africa and Zambia 0-6 months after ART initiation or re-initiation. Protocol PREFER is an observational, prospective cohort study of adults on ART for ≤6 months at 12 public healthcare facilities in Zambia and 18 in South Africa. Its objective is to describe and understand the needs and preferences of initiating and re-initiating ART clients to inform the design of DSD models for the early HIV treatment period, improve early treatment outcomes, and distinguish the barriers encountered by naïve patients from those facing re-initiators. It has four components: 1) survey of clients 0-6 months after ART initiation (identify characteristics and preferences of clients starting ART); 2) follow up through routinely collected medical records for
- Published
- 2024
- Full Text
- View/download PDF
5. Secondary distribution of HIV self-test kits by HIV index and antenatal care clients: implementation and costing results from the STAR Initiative in South Africa
- Author
-
Vincent Zishiri, Donaldson F. Conserve, Zelalem T. Haile, Elizabeth Corbett, Karin Hatzold, Gesine Meyer-Rath, Katleho Matsimela, Linda Sande, Marc d’Elbee, Fern Terris-Prestholt, Cheryl C. Johnson, Thato Chidarikire, Francois Venter, and Mohammed Majam
- Subjects
HIV self-testing ,Secondary distribution ,HIV index clients ,Men ,Linkage to care ,South Africa ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Partner-delivered HIV self-testing kits has previously been highlighted as a safe, acceptable and effective approach to reach men. However, less is known about its real-world implementation in reaching partners of people living with HIV. We evaluated programmatic implementation of partner-delivered self-testing through antenatal care (ANC) attendees and people newly diagnosed with HIV by assessing use, positivity, linkage and cost per kit distributed. Methods Between April 2018 and December 2019, antenatal care (ANC) clinic attendees and people or those newly diagnosed with HIV clients across twelve clinics in three cities in South Africa were given HIVST kits (OraQuick Rapid HIV-1/2 Antibody Test, OraSure Technologies) to distribute to their sexual partners. A follow-up telephonic survey was administered to all prior consenting clients who were successfully reached by telephone to assess primary outcomes. Incremental economic costs of the implementation were estimated from the provider’s perspective. Results Fourteen thousand four hundred seventy-three HIVST kits were distributed – 10,319 (71%) to ANC clients for their male partner and 29% to people newly diagnosed with HIV for their partners. Of the 4,235 ANC clients successfully followed-up, 82.1% (3,475) reportedly offered HIVST kits to their male partner with 98.1% (3,409) accepting and 97.6% (3,328) using the kit. Among ANC partners self-testing, 159 (4.8%) reported reactive HIVST results, of which 127 (79.9%) received further testing; 116 (91.3%) were diagnosed with HIV and 114 (98.3%) initiated antiretroviral therapy (ART). Of the 1,649 people newly diagnosed with HIV successfully followed-up; 1,312 (79.6%) reportedly offered HIVST kits to their partners with 95.8% (1,257) of the partners accepting and 95.9% (1,206) reported that their partners used the kit. Among these index partners, 297 (24.6%) reported reactive HIVST results of which 261 (87.9%) received further testing; 260 (99.6%) were diagnosed with HIV and 258 (99.2%) initiated ART. The average cost per HIVST distributed in the three cities was US$7.90, US$11.98, and US$14.81, respectively. Conclusions Partner-delivered HIVST in real world implementation was able to affordably reach many male partners of ANC attendees and index partners of people newly diagnosed with HIV in South Africa. Given recent COVID-19 related restrictions, partner-delivered HIVST provides an important strategy to maintain essential testing services.
- Published
- 2023
- Full Text
- View/download PDF
6. Costs of facility-based HIV testing in Malawi, Zambia and Zimbabwe.
- Author
-
Lawrence Mwenge, Linda Sande, Collin Mangenah, Nurilign Ahmed, Sarah Kanema, Marc d'Elbée, Euphemia Sibanda, Thokozani Kalua, Gertrude Ncube, Cheryl C Johnson, Karin Hatzold, Frances M Cowan, Elizabeth L Corbett, Helen Ayles, Hendramoorthy Maheswaran, and Fern Terris-Prestholt
- Subjects
Medicine ,Science - Abstract
Providing HIV testing at health facilities remains the most common approach to ensuring access to HIV treatment and prevention services for the millions of undiagnosed HIV-infected individuals in sub-Saharan Africa. We sought to explore the costs of providing these services across three southern African countries with high HIV burden.Primary costing studies were undertaken in 54 health facilities providing HIV testing services (HTS) in Malawi, Zambia and Zimbabwe. Routinely collected monitoring and evaluation data for the health facilities were extracted to estimate the costs per individual tested and costs per HIV-positive individual identified. Costs are presented in 2016 US dollars. Sensitivity analysis explored key drivers of costs.Health facilities were testing on average 2290 individuals annually, albeit with wide variations. The mean cost per individual tested was US$5.03.9 in Malawi, US$4.24 in Zambia and US$8.79 in Zimbabwe. The mean cost per HIV-positive individual identified was US$79.58, US$73.63 and US$178.92 in Malawi, Zambia and Zimbabwe respectively. Both cost estimates were sensitive to scale of testing, facility staffing levels and the costs of HIV test kits.Health facility based HIV testing remains an essential service to meet HIV universal access goals. The low costs and potential for economies of scale suggests an opportunity for further scale-up. However low uptake in many settings suggests that demand creation or alternative testing models may be needed to achieve economies of scale and reach populations less willing to attend facility based services.
- Published
- 2017
- Full Text
- View/download PDF
7. Partner-delivered HIV self-test kits with and without financial incentives in antenatal care and index patients with HIV in Malawi: a three-arm, cluster-randomised controlled trial
- Author
-
Karin Hatzold, Elizabeth L. Corbett, Katherine Fielding, Cheryl Johnson, Augustine T. Choko, Rose Nyirenda, Melissa Neuman, Linda Sande, Richard Chilongosi, Moses Kumwenda, Nicola Desmond, and Rachel C. Baggaley
- Subjects
Adult ,Male ,Malawi ,medicine.medical_specialty ,wc_503_1 ,030231 tropical medicine ,wa_395 ,wc_503 ,HIV Infections ,Context (language use) ,Prenatal care ,Rate ratio ,HIV Testing ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,medicine ,Cluster Analysis ,Humans ,030212 general & internal medicine ,Cluster randomised controlled trial ,Young adult ,Motivation ,Intention-to-treat analysis ,business.industry ,Prenatal Care ,Articles ,General Medicine ,Self-Testing ,Sexual Partners ,Family medicine ,Relative risk ,Cohort ,Female ,Reagent Kits, Diagnostic ,Public aspects of medicine ,RA1-1270 ,business - Abstract
Summary: Background: Secondary distribution of HIV self-testing (HIVST) kits by patients attending clinic services to their partners could improve the rate of HIV diagnosis. We aimed to investigate whether secondary administration of HIVST kits, with or without an additional financial incentive, via women receiving antenatal care (ANC) or via people newly diagnosed with HIV (ie, index patients) could improve the proportion of male partners tested or the number of people newly diagnosed with HIV. Methods: We did a three-arm, open-label, pragmatic, cluster-randomised trial of 27 health centres (clusters), eligible if they were a government primary health centre providing ANC, HIV testing, and ART services, across four districts of Malawi. We recruited women (aged ≥18 years) attending their first ANC visit and whose male partner was available, not already taking ART, and not already tested for HIV during this pregnancy (ANC cohort), and people (aged ≥18 years) with newly diagnosed HIV during routine clinic HIV testing who had at least one sexual contact not already known to be HIV-positive (index cohort). Centres were randomly assigned (1:1:1), using a public selection of computer-generated random allocations, to enhanced standard of care (including an invitation for partners to attend HIV testing services), HIVST only, or HIVST plus a US$10 financial incentive for retesting. The primary outcome for the ANC cohort was the proportion of male partners reportedly tested, as ascertained by interview with women in this cohort at day 28. The primary outcome for the index cohort was the geometric mean number of new HIV-positive people identified per facility within 28 days of enrolment, as measured by observed HIV test results. Cluster-level summaries compared intervention with standard of care by intention to treat. This trial is registered with ClinicalTrials.gov, NCT03705611. Findings: Between Sept 8, 2018, and May 2, 2019, nine clusters were assigned to each trial arm, resulting in 4544 eligible women in the ANC cohort (1447 [31·8%] in the standard care group, 1465 [32·2%] in the HIVST only group, and 1632 [35·9%] in HIVST plus financial incentive group) and 708 eligible patients in the index cohort (234 [33·1%] in the standard care group, 169 [23·9%] in the HIVST only group, and 305 [42·9%] in the HIVST plus financial incentive group). 4461 (98·2%) of 4544 eligible women in the ANC cohort and 645 (91·1%) of 708 eligible patients in the index cohort were recruited, of whom 3378 (75·7%) in the ANC cohort and 439 (68·1%) in the index cohort were interviewed after 28 days. In the ANC cohort, the mean proportion of reported partner testing per cluster was 35·0% (SD 10·0) in the standard care group, 73·0% in HIVST only group (13·1, adjusted risk ratio [RR] 1·71, 95% CI 1·48–1·98; p
- Published
- 2021
- Full Text
- View/download PDF
8. Pragmatic economic evaluation of community-led delivery of HIV self-testing in Malawi
- Author
-
Katherine Fielding, Saviour Mphande, Moses Kumwenda, Hendramoorthy Maheswaran, Karin Hatzold, Rose Nyirenda, Cheryl Johnson, Elizabeth L. Corbett, Pitchaya P. Indravudh, Richard Chilongosi, Linda Sande, and Fern Terris-Prestholt
- Subjects
Marginal cost ,Malawi ,Medicine (General) ,HIV Positivity ,Cost-Benefit Analysis ,HIV Infections ,Infectious and parasitic diseases ,RC109-216 ,HIV Testing ,R5-920 ,other diagnostic or tool ,Economic cost ,Environmental health ,health economics ,Humans ,Medicine ,Cluster randomised controlled trial ,Unit cost ,Original Research ,Health economics ,business.industry ,Health Policy ,Public Health, Environmental and Occupational Health ,HIV ,Self-Testing ,Community health ,Economic evaluation ,cluster randomized trial ,business - Abstract
IntroductionCommunity-based strategies can extend coverage of HIV testing and diagnose HIV at earlier stages of infection but can be costly to implement. We evaluated the costs and effects of community-led delivery of HIV self-testing (HIVST) in Mangochi District, Malawi.MethodsThis economic evaluation was based within a pragmatic cluster-randomised trial of 30 group village heads and their catchment areas comparing the community-led HIVST intervention in addition to the standard of care (SOC) versus the SOC alone. The intervention involved mobilising community health groups to lead 7-day HIVST campaigns including distribution of HIVST kits. The SOC included facility-based HIV testing services. Primary costings estimated economic costs of the intervention and SOC from the provider perspective, with costs annualised and measured in 2018 US$. A postintervention survey captured individual-level data on HIV testing events, which were combined with unit costs from primary costings, and outcomes. The incremental cost per person tested HIV-positive and associated uncertainty were estimated.ResultsOverall, the community-led HIVST intervention costed $138 624 or $5.70 per HIVST kit distributed, with test kits and personnel the main contributing costs. The SOC costed $263 400 or $4.57 per person tested. Individual-level provider costs were higher in the community-led HIVST arm than the SOC arm (adjusted mean difference $3.77, 95% CI $2.44 to $5.10; pConclusionCommunity-led HIVST can provide HIV testing at a low additional unit cost. However, adding community-led HIVST to the SOC was not likely to be cost-effective, especially in contexts with low prevalence of undiagnosed HIV.Trial registration numberNCT03541382.
- Published
- 2021
9. The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis
- Author
-
Lise Jamieson, Linda Sande, Brooke E Nichols, Gesine Meyer-Rath, Marc d'Elbée, Leigh F. Johnson, Karin Hatzold, Thato Chidarikire, Fern Terris-Prestholt, Katleho Matsimela, Mohammed Majam, and Cheryl Johnson
- Subjects
Medicine (General) ,Cost effectiveness ,Cost-Benefit Analysis ,Human immunodeficiency virus (HIV) ,Distribution (economics) ,HIV Infections ,Infectious and parasitic diseases ,RC109-216 ,medicine.disease_cause ,South Africa ,R5-920 ,Acquired immunodeficiency syndrome (AIDS) ,Pregnancy ,Economic cost ,Medicine ,health economics ,Humans ,Mass Screening ,Mass screening ,Original Research ,Health economics ,Cost–benefit analysis ,business.industry ,Health Policy ,Public Health, Environmental and Occupational Health ,HIV ,medicine.disease ,Self-Testing ,Female ,business ,Demography - Abstract
BackgroundHIV self-testing (HIVST) has been shown to be acceptable, feasible and effective in increasing HIV testing uptake. Novel testing strategies are critical to achieving the UNAIDS target of 95% HIV-positive diagnosis by 2025 in South Africa and globally.MethodsWe modelled the impact of six HIVST kit distribution modalities (community fixed-point, taxi ranks, workplace, partners of primary healthcare (PHC) antiretroviral therapy (ART) patients), partners of pregnant women, primary PHC distribution) in South Africa over 20 years (2020–2039), using data collected alongside the Self-Testing AfRica Initiative. We modelled two annual distribution scenarios: (A) 1 million HIVST kits (current) or (B) up to 6.7 million kits. Incremental economic costs (2019 US$) were estimated from the provider perspective; assumptions on uptake and screening positivity were based on surveys of a subset of kit recipients and modelled using the Thembisa model. Cost-effectiveness of each distribution modality compared with the status-quo distribution configuration was estimated as cost per life year saved (estimated from life years lost due to AIDS) and optimised using a fractional factorial design.ResultsThe largest impact resulted from secondary HIVST distribution to partners of ART patients at PHC (life years saved (LYS): 119 000 (scenario A); 393 000 (scenario B)). However, it was one of the least cost-effective modalities (A: $1394/LYS; B: $4162/LYS). Workplace distribution was cost-saving ($52–$76 million) and predicted to have a moderate epidemic impact (A: 40 000 LYS; B: 156 000 LYS). An optimised scale-up to 6.7 million tests would result in an almost threefold increase in LYS compared with a scale-up of status-quo distribution (216 000 vs 75 000 LYS).ConclusionOptimisation-informed distribution has the potential to vastly improve the impact of HIVST. Using this approach, HIVST can play a key role in improving the long-term health impact of investment in HIVST.
- Published
- 2021
10. The cost and intermediary cost-effectiveness of oral HIV self-test kit distribution across 11 distribution models in South Africa
- Author
-
Katleho Matsimela, Karin Hatzold, Celeste Madondo, Gesine Meyer-Rath, Cheryl Johnson, Vincent Zishiri, Fern Terris-Prestholt, Cyprian M. Mostert, Thato Chidarikire, Marc d'Elbée, Jane Phiri, Stephen Khama, Linda Sande, and Mohammed Majam
- Subjects
Medicine (General) ,HIV Positivity ,Cost effectiveness ,Cost-Benefit Analysis ,Human immunodeficiency virus (HIV) ,Distribution (economics) ,HIV Infections ,Infectious and parasitic diseases ,RC109-216 ,other study design ,medicine.disease_cause ,South Africa ,R5-920 ,Acquired immunodeficiency syndrome (AIDS) ,medicine ,Humans ,Mass Screening ,health economics ,Original Research ,Health economics ,business.industry ,Health Policy ,Public Health, Environmental and Occupational Health ,Health services research ,HIV ,medicine.disease ,health services research ,AIDS ,Self-Testing ,business ,Self test ,Demography - Abstract
BackgroundCountries around the world seek innovative ways of closing their remaining gaps towards the target of 95% of people living with HIV (PLHIV) knowing their status by 2030. Offering kits allowing HIV self-testing (HIVST) in private might help close these gaps.MethodsWe analysed the cost, use and linkage to onward care of 11 HIVST kit distribution models alongside the Self-Testing AfRica Initiative’s distribution of 2.2 million HIVST kits in South Africa in 2018/2019. Outcomes were based on telephonic surveys of 4% of recipients; costs on a combination of micro-costing, time-and-motion and expenditure analysis. Costs were calculated from the provider perspective in 2019 US$, as incremental costs in integrated and full costs in standalone models.ResultsHIV positivity among kit recipients was 4%–23%, with most models achieving 5%–6%. Linkage to confirmatory testing and antiretroviral therapy (ART) initiation for those screening positive was 19%–78% and 2%–72% across models. Average costs per HIVST kit distributed varied between $4.87 (sex worker model) and $18.07 (mobile integration model), with differences largely driven by kit volumes. HIVST kit costs (at $2.88 per kit) and personnel costs were the largest cost items throughout. Average costs per outcome increased along the care cascade, with the sex worker network model being the most cost-effective model across metrics used (cost per kit distributed/recipient screening positive/confirmed positive/initiating ART). Cost per person confirmed positive for HIVST was higher than standard HIV testing.ConclusionHIV self-test distribution models in South Africa varied widely along four characteristics: distribution volume, HIV positivity, linkage to care and cost. Volume was highest in models that targeted public spaces with high footfall (flexible community, fixed point and transport hub distribution), followed by workplace models. Transport hub, workplace and sex worker models distributed kits in the least costly way. Distribution via index cases at facility as well as sex worker network distribution identified the highest number of PLHIV at lowest cost.
- Published
- 2021
11. Costs of integrating HIV self-testing in public health facilities in Malawi, South Africa, Zambia and Zimbabwe
- Author
-
Fern Terris-Prestholt, Lawrence Mwenge, Marc d'Elbée, Euphemia L Sibanda, Helen Ayles, Mohammed Majam, Elizabeth L. Corbett, Linda Sande, Frances M. Cowan, Cheryl Johnson, Melissa Neuman, Augustine T. Choko, Karin Hatzold, Cyprian M. Mostert, Katleho Matsimela, Inonge Matamwandi, Gesine Meyer-Rath, Collin Mangenah, and Hendramoorthy Maheswaran
- Subjects
Zimbabwe ,medicine.medical_specialty ,Medicine (General) ,Malawi ,Zambia ,HIV Infections ,Infectious and parasitic diseases ,RC109-216 ,diagnostics and tools ,South Africa ,R5-920 ,Acquired immunodeficiency syndrome (AIDS) ,Environmental health ,medicine ,Humans ,Mass Screening ,health economics ,Human resources ,Activity-based costing ,Average cost ,Original Research ,Health economics ,business.industry ,Health Policy ,Public health ,public health ,Public Health, Environmental and Occupational Health ,HIV ,medicine.disease ,AIDS ,Self-Testing ,Cost driver ,Scale (social sciences) ,Health Facilities ,business - Abstract
IntroductionAs countries approach the UNAIDS 95-95-95 targets, there is a need for innovative and cost-saving HIV testing approaches that can increase testing coverage in hard-to-reach populations. The HIV Self-Testing Africa-Initiative distributed HIV self-test (HIVST) kits using unincentivised HIV testing counsellors across 31 public facilities in Malawi, South Africa, Zambia and Zimbabwe. HIVST was distributed either through secondary (partner’s use) distribution alone or primary (own use) and secondary distribution approaches.MethodsWe evaluated the costs of adding HIVST to existing HIV testing from the providers’ perspective in the 31 public health facilities across the four countries between 2018 and 2019. We combined expenditure analysis and bottom-up costing approaches. We also carried out time-and-motion studies on the counsellors to estimate the human resource costs of introducing and demonstrating how to use HIVST for primary and secondary use.ResultsA total of 41 720 kits were distributed during the analysis period, ranging from 1254 in Zimbabwe to 27 678 in Zambia. The cost per kit distributed through the primary distribution approach was $4.27 in Zambia and $9.24 in Zimbabwe. The cost per kit distributed through the secondary distribution approach ranged from $6.46 in Zambia to $13.42 in South Africa, with a wider variation in the average cost at facility-level. From the time-and-motion observations, the counsellors spent between 20% and 44% of the observed workday on HIVST. Overall, personnel and test kit costs were the main cost drivers.ConclusionThe average costs of distributing HIVST kits were comparable across the four countries in our analysis despite wide cost variability within countries. We recommend context-specific exploration of potential efficiency gains from these facility-level cost variations and demand creation activities to ensure continued affordability at scale.
- Published
- 2021
12. Using HIV self-testing to increase the affordability of community-based HIV testing services
- Author
-
Gesine Meyer-Rath, Cheryl Johnson, Fern Terris-Prestholt, Karin Hatzold, Cyril Nkomo, Albert Machinda, Molemo Charles Makhetha, Matee Taole, Marc d'Elbée, Gabriela B Gomez Guillen, Mphotleng Tlhomola, Elizabeth L. Corbett, Linda Sande, and Makhahliso Jubilee
- Subjects
0301 basic medicine ,Marginal cost ,Community-Based Participatory Research ,Epidemiology and Social ,Longitudinal data ,Immunology ,HIV self-testing ,Human immunodeficiency virus (HIV) ,Financial plan ,HIV Infections ,Hiv testing ,medicine.disease_cause ,costs and cost analysis ,HIV Testing ,03 medical and health sciences ,0302 clinical medicine ,HIV testing services, community-based ,medicine ,Humans ,Mass Screening ,Immunology and Allergy ,Operations management ,Community Health Services ,030212 general & internal medicine ,Lesotho, southern Africa ,Community based ,Priority setting ,Lesotho ,Self-Testing ,030104 developmental biology ,Infectious Diseases ,efficiency ,Resource use ,Business - Abstract
Objectives This study estimates the costs of community-based HIV testing services (HTS) in Lesotho and assesses the potential efficiency gains achieved by adding HIV self-testing (HIVST) and then self-testing booths. Design Micro-costing analysis using longitudinal data from a real-world intervention. Methods We collected data prospectively on provider's costs and programmatic outcomes over three time periods of approximately eight months each, between May 2017 and April 2019. The scope of services was extended during each period as follows: 1) HTS only, 2) HTS and HIVST, 3) HTS and HIVST with individual HIVST booths where clients were encouraged to self-test on-site followed by on-site confirmative testing for those with reactive self-test. For each implementation period, we estimated the full financial and economic implementation costs, the incremental costs of adding HIVST onto conventional HTS and the cost per HIV positive case identified. Results Costs per HIV-positive case identified increased between period 1 (US$956) and period 2 (US$1,249) then dropped in period 3 (US$813). Full versus incremental cost analyses resulted in large differences in the magnitude of costs, attributable to methods rather than resource use: e.g. in period 3, the average full and incremental cost estimates for HTS were US$34.3 and US$23.5 per person tested, and for HIVST were US$37.7 and US$14.0 per kit provided, respectively. Conclusions In Lesotho, adding HIVST to community-based HTS improves its overall affordability regarding HIV-positive case finding. The reporting of both full and incremental cost estimates increase transparency for use in priority setting, budgeting and financial planning for scale-up.
- Published
- 2020
13. A Systematic Literature Review of Preference-Based Health-Related Quality-of-Life Measures Applied and Validated for Use in Childhood and Adolescent Populations in Sub-Saharan Africa
- Author
-
Louis W. Niessen, Lucky-Gift Ngwira, Linda Sande, Sarah Smith, Kamran Khan, Hendramoorthy Maheswaran, Stavros Petrou, and Linda Nyondo-Mipando
- Subjects
Gerontology ,Adult ,Sub saharan ,Adolescent ,Health Status ,Economics, Econometrics and Finance (miscellaneous) ,MEDLINE ,PsycINFO ,EconLit ,03 medical and health sciences ,South Africa ,0302 clinical medicine ,Humans ,030212 general & internal medicine ,Child ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,Equivalence (measure theory) ,030503 health policy & services ,Health Policy ,Preference ,Systematic review ,Research Design ,Quality of Life ,0305 other medical science ,Psychology ,Health Utilities Index - Abstract
Objectives Consideration of health status in children and adolescents now includes broader concepts such as health-related quality-of-life (HRQoL). Globally, there is a need for relevant preference-based HRQoL measures (PBMs) for use in children and adolescents, yet measurement of HRQoL in these groups presents particular challenges. This article systematically reviews the available generic childhood PBMs and their application and cross-cultural validation in sub-Saharan African (sSA). Methods A systematic review of published literature from January 1, 1990, to February 8, 2017, was conducted using MEDLINE (through OvidSP), EMBASE (OvidSP), EconLit (EBSCOhost), PsycINFO, Web of Science, and PubMed. Results A total of 220 full-text articles were included in a qualitative synthesis. Ten generic childhood PBMs were identified, of which 9 were adapted from adult versions and only 1 was developed specifically for children. None of the measures were originally developed in sSA or other resource-constrained settings. The Health Utilities Index Mark 3 (HUI3) and the EQ-5D-Y were the only measures that had been applied in sSA settings. Further, the HUI3 and the EQ-5D-Y were the only generic childhood PBM that attempted to establish cross-cultural validation in sSA. Five of the 6 of these validation studies were conducted using the EQ-5D-Y in a single country, South Africa. Conclusions The findings show that application of generic childhood PBMs in sSA settings has hitherto been limited to the HUI3 and EQ-5D-Y. Most adaptations of existing measures take an absolutist approach, which assumes that measures can be used across cultures. Nevertheless, there is also need to ensure linguistic and conceptual equivalence and undertake validation across a range of sSA cultural contexts.
- Published
- 2020
14. Costs of accessing HIV testing services among rural Malawi communities
- Author
-
Karin Hatzold, Melissa Neuman, Phillip Mkandawire, Collin Mangenah, Hendramoorthy Maheswaran, Elizabeth L. Corbett, Pitchaya P. Indravudh, Marc d'Elbée, Fern Terris-Prestholt, Lawrence Mwenge, Linda Sande, Cheryl Johnson, and Nurilign Ahmed
- Subjects
0301 basic medicine ,Service (business) ,Health (social science) ,Social Psychology ,business.industry ,Total cost ,total costs ,Public Health, Environmental and Occupational Health ,HIV ,Articles ,Hiv testing ,Disease cluster ,030112 virology ,Odds ,Test (assessment) ,03 medical and health sciences ,Indirect costs ,0302 clinical medicine ,Environmental health ,Medicine ,Residence ,030212 general & internal medicine ,business ,health care economics and organizations ,HIV testing and counseling - Abstract
HIV testing is free in Malawi, but users may still incur costs that can deter or delay them accessing these services. We sought to identify and quantify these costs among HIV testing service clients in Malawi. We asked residents of communities participating in a cluster randomised trial investigating the impact of HIV self-testing about their past HIV testing experiences and the direct non-medical and indirect costs incurred to access HIV testing. We recruited 749 participants whose most recent HIV test was within the past 12 months. The mean total cost to access testing was US$2.45 (95%CI: US$2.11–US$2.70). Men incurred higher costs (US$3.81; 95%CI: US$2.91–US$4.50) than women (US$1.83; 95%CI: US$1.61–US$2.00). Results from a two-part multivariable regression analysis suggest that age, testing location, time taken to test, visiting a facility specifically for an HIV test and district of residence significantly affected the odds of incurring costs to testing. In addition, gender, wealth, age, education and district of residence were associated with significant user costs.
- Published
- 2018
- Full Text
- View/download PDF
15. Interstitial macrophage phenotypes in Schistosoma-induced pulmonary hypertension
- Author
-
Rahul Kumar, Sushil Kumar, Claudia Mickael, Dara Fonseca Balladares, Kevin Nolan, Michael H. Lee, Linda Sanders, Julia Nilsson, Ari B. Molofsky, Rubin M. Tuder, Kurt R. Stenmark, and Brian B. Graham
- Subjects
macrophages ,inflammation ,schistosomiasis ,pulmonary hypertension ,type 2 inflammation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundSchistosomiasis is a common cause of pulmonary hypertension (PH) worldwide. Type 2 inflammation contributes to the development of Schistosoma-induced PH. Specifically, interstitial macrophages (IMs) derived from monocytes play a pivotal role by producing thrombospondin-1 (TSP-1), which in turn activates TGF-β, thereby driving the pathology of PH. Resident and recruited IM subpopulations have recently been identified. We hypothesized that in Schistosoma-PH, one IM subpopulation expresses monocyte recruitment factors, whereas recruited monocytes become a separate IM subpopulation that expresses TSP-1.MethodsMice were intraperitoneally sensitized and then intravenously challenged with S. mansoni eggs. Flow cytometry on lungs and blood was performed on wildtype and reporter mice to identify IM subpopulations and protein expression. Single-cell RNA sequencing (scRNAseq) was performed on flow-sorted IMs from unexposed and at day 1, 3 and 7 following Schistosoma exposure to complement flow cytometry based IM characterization and identify gene expression.ResultsFlow cytometry and scRNAseq both identified 3 IM subpopulations, characterized by CCR2, MHCII, and FOLR2 expression. Following Schistosoma exposure, the CCR2+ IM subpopulation expanded, suggestive of circulating monocyte recruitment. Schistosoma exposure caused increased monocyte-recruitment ligand CCL2 expression in the resident FOLR2+ IM subpopulation. In contrast, the vascular pathology-driving protein TSP-1 was greatest in the CCR2+ IM subpopulation.ConclusionSchistosoma-induced PH involves crosstalk between IM subpopulations, with increased expression of monocyte recruitment ligands by resident FOLR2+ IMs, and the recruitment of CCR2+ IMs which express TSP-1 that activates TGF-β and causes PH.
- Published
- 2024
- Full Text
- View/download PDF
16. Modelling costs of community-based HIV self-testing programmes in Southern Africa at scale: an econometric cost function analysis across five countries
- Author
-
Melissa Neuman, Karin Hatzold, Collin Mangenah, Graham F. Medley, Gabriela B. Gomez, Fern Terris-Prestholt, Gesine Meyer-Rath, Cheryl Johnson, Linda Sande, Marc d'Elbée, Lawrence Mwenge, and Elizabeth L. Corbett
- Subjects
Male ,Medicine (General) ,Malawi ,Distribution (economics) ,Financial plan ,HIV Infections ,Context (language use) ,Infectious and parasitic diseases ,RC109-216 ,Africa, Southern ,Gross domestic product ,R5-920 ,Economic cost ,Econometrics ,Per capita ,health economics ,Humans ,Mass Screening ,Original Research ,Health economics ,business.industry ,Health Policy ,Public Health, Environmental and Occupational Health ,HIV ,health services research ,Self-Testing ,Scale (social sciences) ,business - Abstract
BackgroundFollowing success demonstrated with the HIV Self-Testing AfRica Initiative, HIV self-testing (HIVST) is being added to national HIV testing strategies in Southern Africa. An analysis of the costs of scaling up HIVST is needed to inform national plans, but there is a dearth of evidence on methods for forecasting costs at scale from pilot projects. Econometric cost functions (ECFs) apply statistical inference to predict costs; however, we often do not have the luxury of collecting large amounts of location-specific data. We fit an ECF to identify key drivers of costs, then use a simpler model to guide cost projections at scale.MethodsWe estimated the full economic costs of community-based HIVST distribution in 92 locales across Malawi, Zambia, Zimbabwe, South Africa and Lesotho between June 2016 and June 2019. We fitted a cost function with determinants related to scale, locales organisational and environmental characteristics, target populations, and per capita Growth Domestic Product (GDP). We used models differing in data intensity to predict costs at scale. We compared predicted estimates with scale-up costs in Lesotho observed over a 2-year period.ResultsThe scale of distribution, type of community-based intervention, percentage of kits distributed to men, distance from implementer’s warehouse and per capita GDP predicted average costs per HIVST kit distributed. Our model simplification approach showed that a parsimonious model could predict costs without losing accuracy. Overall, ECF showed a good predictive capacity, that is, forecast costs were close to observed costs. However, at larger scale, variations of programme efficiency over time (number of kits distributed per agent monthly) could potentially influence cost predictions.DiscussionOur empirical cost function can inform community-based HIVST scale-up in Southern African countries. Our findings suggest that a parsimonious ECF can be used to forecast costs at scale in the context of financial planning and budgeting.
- Published
- 2021
- Full Text
- View/download PDF
17. Economic cost analysis of door-to-door community-based distribution of HIV self-test kits in Malawi, Zambia and Zimbabwe
- Author
-
Cheryl Johnson, Linda Sande, Frances M. Cowan, Karin Hatzold, Melissa Neuman, Tariro Chigwenah, Jason J. Ong, Collin Mangenah, Nurilign Ahmed, Hendramoorthy Maheswaran, Pitchaya P. Indravudh, Elizabeth L. Corbett, Owen Mugurungi, Getrude Ncube, Lawrence Mwenge, Richard Chilongosi, Marc d'Elbée, Helen Ayles, Sarah Kanema, Euphemia L Sibanda, Miriam N Mutseta, Mutinta Nalubamba, Fern Terris-Prestholt, and Progress Chiwawa
- Subjects
Zimbabwe ,Male ,Malawi ,Total cost ,Zambia ,Distribution (economics) ,HIV Infections ,World Health Organization ,costs and cost analysis ,Unit (housing) ,03 medical and health sciences ,0302 clinical medicine ,Economic cost ,Humans ,Mass Screening ,Medicine ,Serologic Tests ,030212 general & internal medicine ,Fixed cost ,Socioeconomics ,Research Articles ,HIV self‐testing ,Average cost ,030505 public health ,business.industry ,1. No poverty ,Public Health, Environmental and Occupational Health ,Monitoring and evaluation ,3. Good health ,Economies of scale ,Infectious Diseases ,community ,0305 other medical science ,business ,Delivery of Health Care ,Research Article - Abstract
Introduction HIV self‐testing (HIVST) is recommended by the World Health Organization in addition to other testing modalities to increase uptake of HIV testing, particularly among harder‐to‐reach populations. This study provides the first empirical evidence of the costs of door‐to‐door community‐based HIVST distribution in Malawi, Zambia and Zimbabwe. Methods HIVST kits were distributed door‐to‐door in 71 sites across Malawi, Zambia and Zimbabwe from June 2016 to May 2017. Programme expenditures, supplemented by on‐site observation and monitoring and evaluation data were used to estimate total economic and unit costs of HIVST distribution, by input and site. Inputs were categorized into start‐up, capital and recurrent costs. Sensitivity and scenario analyses were performed to assess the impact of key parameters on unit costs. Results In total, 152,671, 103,589 and 93,459 HIVST kits were distributed in Malawi, Zambia and Zimbabwe over 12, 11 and 10 months respectively. Across these countries, 43% to 51% of HIVST kits were distributed to men. The average cost per HIVST kit distributed was US$8.15, US$16.42 and US$13.84 in Malawi, Zambia and Zimbabwe, respectively, with pronounced intersite variation within countries driven largely by site‐level fixed costs. Site‐level recurrent costs were 70% to 92% of full costs and 20% to 62% higher than routine HIV testing services (HTS) costs. Personnel costs contributed from 26% to 52% of total costs across countries reflecting differences in remuneration approaches and country GDP. Conclusions These early door‐to‐door community HIVST distribution programmes show large potential, both for reaching untested populations and for substantial economies of scale as HIVST programmes scale‐up and mature. From a societal perspective, the costs of HIVST appear similar to conventional HTS, with the higher providers’ costs substantially offsetting user costs. Future approaches to minimizing cost and/or maximize testing coverage could include unpaid door‐to‐door community‐led distribution to reach end‐users and integrating HIVST into routine clinical services via direct or secondary distribution strategies with lower fixed costs.
- Published
- 2019
18. Experimental Schistosoma haematobium pulmonary hypertension
- Author
-
Biruk Kassa, Dara C. Fonseca‐Balladares, Rahul Kumar, Michael H. Lee, Claudia Mickael, Linda Sanders, Kevin Nolan, and Brian B. Graham
- Subjects
parasitic infections ,pulmonary hypertension ,pulmonary hypertension experimental ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Whether all Schistosoma species cause pulmonary hypertension (PH) is unclear. Experimentally exposing mice to Schistosoma haematobium eggs caused PH, which was less severe than that induced by S. mansoni exposure. These findings align with the relatively uncommon reports of pulmonary arterial hypertension associated with S. haematobium.
- Published
- 2024
- Full Text
- View/download PDF
19. Costs of facility-based HIV testing in Malawi, Zambia and Zimbabwe
- Author
-
Gertrude Ncube, Karin Hatzold, Linda Sande, Marc d'Elbée, Lawrence Mwenge, Helen Ayles, Thokozani Kalua, Nurilign Ahmed, Frances M. Cowan, Fern Terris-Prestholt, Euphemia L Sibanda, Cheryl Johnson, Sarah Kanema, Elizabeth L. Corbett, Collin Mangenah, and Hendramoorthy Maheswaran
- Subjects
0301 basic medicine ,RNA viruses ,Malawi ,Cost estimate ,Economics ,Epidemiology ,lcsh:Medicine ,Social Sciences ,wc_503 ,HIV Infections ,Pathology and Laboratory Medicine ,Geographical Locations ,0302 clinical medicine ,Health facility ,Immunodeficiency Viruses ,Medicine and Health Sciences ,Mass Screening ,030212 general & internal medicine ,lcsh:Science ,Activity-based costing ,wa_30 ,Multidisciplinary ,virus diseases ,HIV diagnosis and management ,Health Care Costs ,3. Good health ,Medical Microbiology ,HIV epidemiology ,Scale (social sciences) ,Viral Pathogens ,Viruses ,Pathogens ,Research Article ,Zimbabwe ,wc_503_1 ,HIV prevention ,Staffing ,Zambia ,41b6e438 ,Microbiology ,03 medical and health sciences ,Environmental health ,Retroviruses ,Humans ,Microbial Pathogens ,Service (business) ,Preventive medicine ,lcsh:R ,Lentivirus ,Organisms ,Biology and Life Sciences ,HIV ,Monitoring and evaluation ,Patient Acceptance of Health Care ,030112 virology ,Diagnostic medicine ,Economies of scale ,Public and occupational health ,People and Places ,Africa ,Feasibility Studies ,lcsh:Q ,Business ,Health Facilities ,Finance - Abstract
BACKGROUND: Providing HIV testing at health facilities remains the most common approach to ensuring access to HIV treatment and prevention services for the millions of undiagnosed HIV-infected individuals in sub-Saharan Africa. We sought to explore the costs of providing these services across three southern African countries with high HIV burden. METHODS: Primary costing studies were undertaken in 54 health facilities providing HIV testing services (HTS) in Malawi, Zambia and Zimbabwe. Routinely collected monitoring and evaluation data for the health facilities were extracted to estimate the costs per individual tested and costs per HIV-positive individual identified. Costs are presented in 2016 US dollars. Sensitivity analysis explored key drivers of costs. RESULTS: Health facilities were testing on average 2290 individuals annually, albeit with wide variations. The mean cost per individual tested was US$5.03.9 in Malawi, US$4.24 in Zambia and US$8.79 in Zimbabwe. The mean cost per HIV-positive individual identified was US$79.58, US$73.63 and US$178.92 in Malawi, Zambia and Zimbabwe respectively. Both cost estimates were sensitive to scale of testing, facility staffing levels and the costs of HIV test kits. CONCLUSIONS: Health facility based HIV testing remains an essential service to meet HIV universal access goals. The low costs and potential for economies of scale suggests an opportunity for further scale-up. However low uptake in many settings suggests that demand creation or alternative testing models may be needed to achieve economies of scale and reach populations less willing to attend facility based services.
- Published
- 2017
20. The role of macrophages in right ventricular remodeling in experimental pulmonary hypertension
- Author
-
Sue Gu, Claudia Mickael, Rahul Kumar, Michael H. Lee, Linda Sanders, Biruk Kassa, Julie Harral, Jason Williams, Kirk C. Hansen, Kurt R. Stenmark, Rubin M. Tuder, and Brian B. Graham
- Subjects
adaptation ,hypoxia ,inflammation ,right heart ,Schistosoma ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Right ventricular (RV) failure is the primary cause of death in pulmonary hypertension (PH), but the mechanisms of RV failure are not well understood. We hypothesized macrophages in the RV contribute to the RV response in PH. We induced PH in mice with hypoxia (FiO2 10%) and Schistosoma mansoni exposure, and in rats with SU5416‐hypoxia. We quantified cardiac macrophages in mice using flow cytometry. Parabiosis between congenic CD45.1/.2 mice or Cx3cr1‐green fluorescent protein and wild‐type mice was used to quantify circulation‐derived macrophages in experimental PH conditions. We administered clodronate liposomes to Sugen hypoxia (SU‐Hx) exposed rats to deplete macrophages and evaluated the effect on the extracellular matrix (ECM) and capillary network in the RV. In hypoxia exposed mice, the overall number of macrophages did not significantly change but two macrophage subpopulations increased. Parabiosis identified populations of RV macrophages that at steady state is derived from the circulation, with one subpopulation that significantly increased with PH stimuli. Clodronate treatment of SU‐Hx rats resulted in a change in the RV ECM, without altering the RV vasculature, and correlated with improved RV function. Populations of RV macrophages increase and contribute to RV remodeling in PH, including through regulation of the RV ECM.
- Published
- 2022
- Full Text
- View/download PDF
21. Experimental Schistosoma japonicum-induced pulmonary hypertension.
- Author
-
Biruk Kassa, Michael H Lee, Rahul Kumar, Claudia Mickael, Linda Sanders, Rubin M Tuder, Margaret Mentink-Kane, and Brian B Graham
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundSchistosomiasis, a major cause of pulmonary arterial hypertension (PAH) worldwide, is most clearly described complicating infection by one species, Schistosoma mansoni. Controlled exposure of mice can be used to induce Type 2 inflammation-dependent S. mansoni pulmonary hypertension (PH). We sought to determine if another common species, S. japonicum, can also cause experimental PH.MethodsSchistosome eggs were obtained from infected mice, and administered by intraperitoneal sensitization followed by intravenous challenge to experimental mice, which underwent right heart catheterization and tissue analysis.ResultsS. japonicum sensitized and challenged mice developed PH, which was milder than that following S. mansoni sensitization and challenge. The degree of pulmonary vascular remodeling and Type 2 inflammation in the lungs was similarly proportionate. Cross-sensitization revealed that antigens from either species are sufficient to sensitize for intravenous challenge with either egg, and the degree of PH severity depended on primarily the species used for intravenous challenge. Compared to a relatively uniform distribution of S. mansoni eggs, S. japonicum eggs were observed in clusters in the lungs.ConclusionsS. japonicum can induce experimental PH, which is milder than that resulting from comparable S. mansoni exposure. This difference may result from the distribution of eggs in the lungs, and is independent of which species is used for sensitization. This result is consistent with the clearer association between S. mansoni infection and the development of schistosomiasis-associated PAH in humans.
- Published
- 2022
- Full Text
- View/download PDF
22. Epithelial/mesenchymal heterogeneity of high‐grade serous ovarian carcinoma samples correlates with miRNA let‐7 levels and predicts tumor growth and metastasis
- Author
-
Evgeny Chirshev, Nozomi Hojo, Antonella Bertucci, Linda Sanderman, Anthony Nguyen, Hanmin Wang, Tise Suzuki, Emmanuel Brito, Shannalee R. Martinez, Christine Castañón, Saied Mirshahidi, Marcelo E. Vazquez, Pamela Wat, Kerby C. Oberg, Yevgeniya J. Ioffe, and Juli J. Unternaehrer
- Subjects
epithelial/mesenchymal transition ,high‐grade serous ovarian cancer ,microRNA ,orthotopic patient‐derived xenografts ,stem cells ,transcriptional regulation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Patient‐derived samples present an advantage over current cell line models of high‐grade serous ovarian cancer (HGSOC) that are not always reliable and phenotypically faithful models of in vivo HGSOC. To improve upon cell line models of HGSOC, we set out to characterize a panel of patient‐derived cells and determine their epithelial and mesenchymal characteristics. We analyzed RNA and protein expression levels in patient‐derived xenograft (PDX) models of HGSOC, and functionally characterized these models using flow cytometry, wound healing assays, invasion assays, and spheroid cultures. Besides in vitro work, we also evaluated the growth characteristics of PDX in vivo (orthotopic PDX). We found that all samples had hybrid characteristics, covering a spectrum from an epithelial‐to‐mesenchymal state. Samples with a stronger epithelial phenotype were more active in self‐renewal assays and more tumorigenic in orthotopic xenograft models as compared to samples with a stronger mesenchymal phenotype, which were more migratory and invasive. Additionally, we observed an inverse association between microRNA let‐7 (lethal‐7) expression and stemness, consistent with the loss of let‐7 being an important component of the cancer stem cell phenotype. We observed that lower let‐7 levels were associated with the epithelial state and a lower epithelial mesenchymal transition (EMT) score, more efficient spheroid and tumor formation, and increased sensitivity to platinum‐based chemotherapy. Surprisingly, in these HGSOC cells, stemness could be dissociated from invasiveness: Cells with lower let‐7 levels were more tumorigenic, but less migratory, and with a lower EMT score, than those with higher let‐7 levels. We conclude that let‐7 expression and epithelial/mesenchymal state are valuable predictors of HGSOC proliferation, in vitro self‐renewal, and tumor burden in vivo.
- Published
- 2020
- Full Text
- View/download PDF
23. Kikuchi Disease with enlargement of intramammary lymph node
- Author
-
Michael A Simon, MD, Linda Sanders, MD, Dina Morgan, DO, Syed Abbas, MD, and Matthew Tortora, MD
- Subjects
Kikuchi-Fujimoto Disease ,Lymphadenopathy ,Intramammary lymph node ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
We describe a rare case of intramammary lymphadenopathy due to Kikuchi-Fujimoto disease. A 15-year old female presented to the Breast Clinic with complaints of a tender, palpable right breast lump. An ultrasound of the area of concern demonstrated an enlarged 2.9 cm intramammary lymph node with preservation of the fatty hilum. An ultrasound guided core biopsy of the lymph node confirmed the diagnosis of Kikuchi-Fujimoto disease.
- Published
- 2021
- Full Text
- View/download PDF
24. TGF-β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension
- Author
-
Rahul Kumar, Claudia Mickael, Biruk Kassa, Liya Gebreab, Jeffrey C. Robinson, Daniel E. Koyanagi, Linda Sanders, Lea Barthel, Christina Meadows, Daniel Fox, David Irwin, Min Li, B. Alexandre McKeon, Suzette Riddle, R. Dale Brown, Leslie E. Morgan, Christopher M. Evans, Daniel Hernandez-Saavedra, Angela Bandeira, James P. Maloney, Todd M. Bull, William J. Janssen, Kurt R. Stenmark, Rubin M. Tuder, and Brian B. Graham
- Subjects
Science - Abstract
Thrombospondin-1 (TSP-1) activates latent TGF-β in the extracellular matrix. Here the authors show that inappropriate activation of latent TGF-β in murine, bovine and human lung by monocyte-produced TSP-1 causes pulmonary hypertension, and that interference with the activation process prevents disease development.
- Published
- 2017
- Full Text
- View/download PDF
25. Th2 CD4+ T Cells Are Necessary and Sufficient for Schistosoma‐Pulmonary Hypertension
- Author
-
Rahul Kumar, Claudia Mickael, Biruk Kassa, Linda Sanders, Dan Koyanagi, Daniel Hernandez‐Saavedra, Scott Freeman, Daniel Morales‐Cano, Angel Cogolludo, Amy S. McKee, Andrew P. Fontenot, Ghazwan Butrous, Rubin M. Tuder, and Brian B. Graham
- Subjects
CD4 T cell ,pulmonary hypertension ,schistosomiasis ,type 2 immunity ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Inflammation underlies many forms of pulmonary hypertension (PH), including that resulting from Schistosoma infection, a major cause of PH worldwide. Schistosomiasis‐associated PH is proximately triggered by embolization of parasite eggs into the lungs, resulting in localized type 2 inflammation. However, the role of CD4+ T cells in this disease is not well defined. Methods and Results We used a mouse model of schistosomiasis‐associated PH, induced by intraperitoneal egg sensitization followed by intravenous egg challenge, with outcomes including right ventricle systolic pressure measured by cardiac catheterization, and cell density and phenotype assessed by flow cytometry. We identified that embolization of Schistosoma eggs into lungs of egg‐sensitized mice increased the perivascular density of T‐helper 2 (Th2) CD4+ T cells by recruitment of cells from the circulation and triggered type 2 inflammation. Parabiosis confirmed that egg embolization is required for localized type 2 immunity. We found Th2 CD4+ T cells were necessary for Schistosoma‐induced PH, given that deletion of CD4+ T cells or inhibiting their Th2 function protected against type 2 inflammation and PH following Schistosoma exposure. We also observed that adoptive transfer of Schistosoma‐sensitized CD4+ Th2 cells was sufficient to drive type 2 inflammation and PH. Conclusions Th2 CD4+ T cells are a necessary and sufficient component for the type 2 inflammation‐induced PH following Schistosoma exposure.
- Published
- 2019
- Full Text
- View/download PDF
26. 4575 Implementing a Workflow Management Tool for Clinical Trials
- Author
-
Laura Nelle Hanson, Jennifer Weis, Sasa Andrijasevic, Sharon Elcombe, Rachel Hardtke, Andrea Kukla, and Linda Sanders
- Subjects
Medicine - Abstract
OBJECTIVES/GOALS: A workflow management tool is essential in order to help support consistent processes with transparency in next steps of the study process. Prior to this tool, staff has relied upon extensive training and coaching on the study process. While resources and guidelines exist, it requires additional time for staff to identify these resources and allows for confusion and rework. Implementation of a systematic workflow management tool was identified as a critical need in order to support streamlined processes, improve transparency and support business continuity, and to accelerate the study process. METHODS/STUDY POPULATION: This effort was undertaken as part of the Protocol Lifecycle Management effort to implement a comprehensive clinical trial management system for clinical research studies. Mayo Clinic has designed a workflow management tool within the Velos eResearch system. The workflow manager is dynamic and will present specific activities based on the study design and responses to data entered on the ad hoc forms. A Workflow Build group contributed to the design of the workflow in order to reflect appropriate, current operational processes. The workflow was vetted and validated with research teams. In addition to designing activities, planned dates and target timelines were established for relevant workflows to help promote transparency in the study start-up timelines and allow study staff to identify overdue activities. Study status controls were designed in the workflow to protect study staff from inadvertently changing the status until appropriate activities are complete. RESULTS/ANTICIPATED RESULTS: A dynamic workflow has been designed and implemented in the Velos eResearch system to support Mayo Clinic research sites. This system will be implemented February 24, 2020 to all consenting studies. DISCUSSION/SIGNIFICANCE OF IMPACT: The implementation of this workflow management tool is critical to help support research operations in a large, academic medical center. Benefits to implementation are expected to include improved transparency in the study status and next steps, reductions in rework due to confusion in next steps, better understanding from new staff in the appropriate study process, and improved timelines for study start-up. As we prepare for the implementation of the Velos eResearch system at Mayo Clinic, the workflow management tool has been identified in training sessions as a positive benefit.
- Published
- 2020
- Full Text
- View/download PDF
27. Paclitaxel blocks Th2-mediated TGF-β activation in -induced pulmonary hypertension
- Author
-
Biruk Kassa, Claudia Mickael, Rahul Kumar, Linda Sanders, Dan Koyanagi, Daniel Hernandez-Saavedra, Rubin M. Tuder, and Brian B. Graham
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Diseases of the respiratory system ,RC705-779 - Abstract
Schistosomiasis is a leading cause of pulmonary hypertension (PH) worldwide. Recent studies reveal that the type-2 immune cytokines IL-4 and IL-13, as well as consequent activation of TGF-β, are key factors in the pathogenesis of Schistosoma -PH. Paclitaxel has been reported to act as an adjuvant for Th2 inflammation while downregulating TGF-β activation. Moreover, paclitaxel blocks PH in monocrotaline and SU5416-hypoxia models. We hypothesized that paclitaxel would augment Th2 inflammation while blocking TGF-β activation and PH after schistosomiasis exposure. Wild-type mice (C57BL6/J; 6/group) were intraperitoneally (IP) sensitized and then intravenously (IV) challenged with Schistosoma mansoni eggs. One day after IV egg challenge, the mice were treated with a single IP dose of 25 mg/kg paclitaxel or vehicle. Right ventricular (RV) catheterization was performed and granuloma volumes and vascular remodeling were quantified. Lung cytokines were quantified by ELISA and reverse transcription polymerase chain reaction, and the quantity of active TGF-β was determined using a cell reporter line. We also investigated hypoxia-induced PH. Paclitaxel treatment significantly protected mice from Schistosoma -PH, with decreased RV systolic pressure ( P = 0.005) and pulmonary vascular media thickness. Inflammation was significantly suppressed, contrary to our hypothesis, with decreased IL-4 and IL-13 levels, smaller granulomas, and less active TGF-β following paclitaxel treatment. There was no change in IFN-γ or FoxO1 or FoxO3 expression. Paclitaxel did not suppress chronic hypoxia-induced PH, which is also TGF-β-driven but independent of type-2 immunity. Paclitaxel protects against Schistosoma -induced PH in mice, although by blocking proximate Th2 inflammation rather than suppressing distal TGF-β activation.
- Published
- 2018
- Full Text
- View/download PDF
28. Desarrollo del entorno personal de aprendizaje para tutoría e investigación en niveles educativos superiores
- Author
-
Alma Dzib Goodin, John Castevich, Dolores Luna Hogan, Linda Sanders, Kathleen Slovec, and Daniel Yelizarov
- Subjects
ENTORNOS VIRTUALES ,EDUCACIÓN SUPERIOR ,PLE ,Education ,Special aspects of education ,LC8-6691 - Abstract
El concepto de entorno personal se refiere a los sistemas que facilitan a los aprendices a tomar control de manera autónoma de sus aprendizajes. Esto incluye apoyos para determinar sus propias metas, comprensión de contenidos y de los procesos implicados en el proceso de aprendizaje. Usualmente el mayor impulso se ofrece en torno a las nuevas tecnologías, ya que se supone que el alumno es capaz de interactuar de manera efectiva con los lenguajes y entornos tecnológicos, pues más jóvenes las generaciones, más conocimiento tienen del uso y manejo de la información en medios digitales. Partir de este supuesto, y suponer que el alumno es capaz por sí mismo de encontrar su propio camino, lleva a mucha frustración, especialmente cuando se considera como factor clave las diferencias culturales. El presente trabajo busca reconocer que existen diferencias culturales en el manejo de herramientas que se consideran usuales como las redes sociales para desarrollar propuestas académicas que permitan apoyar el aprendizaje de los estudiantes y se encuentra que existen factores que pueden potencialmente beneficiar o entorpecer el desarrollo académico de los estudiantes si estas no son consideradas en los programas educativos. Reconocer dichas diferencias es clave para trabajar en programas de apoyo a los estudiantes, pues una vez que éstos reconocen sus potencialidades y son capaces de generar las estrategias adecuadas a los requerimientos de las nuevas tecnologías, serán más eficientes en su aprendizaje.
- Published
- 2015
- Full Text
- View/download PDF
29. Novosphingobium and its potential role in chronic obstructive pulmonary diseases: insights from microbiome studies.
- Author
-
Alleluiah Rutebemberwa, Mark J Stevens, Mario J Perez, Lynelle P Smith, Linda Sanders, Gregory Cosgrove, Charles E Robertson, Rubin M Tuder, and J Kirk Harris
- Subjects
Medicine ,Science - Abstract
Bacterial infection of lung airways underlies some of the main complications of COPD, significantly impacting disease progression and outcome. Colonization by bacteria may further synergize, amplify, or trigger pathways of tissue damage started by cigarette smoke, contributing to the characteristic airway inflammation and alveolar destruction of COPD. We sought to elucidate the presence and types of lung bacterial populations in different stages of COPD, aimed at revealing important insights into the pathobiology of the disease. Sequencing of the bacterial small subunit ribosomal RNA gene in 55 well-characterized clinical lung samples, revealed the presence of Novosphingobium spp. (>2% abundance) in lungs of patients with GOLD 3-GOLD 4 COPD, cystic fibrosis and a subset of control individuals. Novosphingobium-specific quantitative PCR was concordant with the sequence data and high levels of Novosphingobium spp. were quantifiable in advanced COPD, but not from other disease stages. Using a mouse model of subacute lung injury due to inhalation of cigarette smoke, bronchoalveolar lavage neutrophil and macrophage counts were significantly higher in mice challenged intratracheally with N. panipatense compared to control mice (p
- Published
- 2014
- Full Text
- View/download PDF
30. Linguistic Contradiction: Power and Politeness in Courtroom Discourse
- Author
-
Linda Sanderson
- Subjects
Discourse analysis ,P302-302.87 - Abstract
This article examines the courtroom as a workplace using Brown and Levinson's politeness model. It is argued that while the model is a valuable tool for analyzing courtroom discourse, the courtroom, as well as institutional and organizational contexts in general, possesses characteristics that demand a more complex contextual analysis. The article first looks at some of the distinct characteristics of language use in a courtroom setting, and then analyzes excerpts drawn from a courtroom transcript. Institutional factors that affect the model's performance in this workplace are delineated. The article concludes that these institutional factors are not unique to the courtroom; they are relevant to understanding language use in many types of workplace, including corporate, public, and organizational contexts.
- Published
- 1995
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.